# Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma

> **NCT00045565** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma

## Interventions

- **DRUG:** arsenic trioxide
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00045565
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2008-11
- **Final completion:** —
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2013-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00045565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00045565, "Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00045565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*